|Other Names||Myotubularin-related protein 6, 313-, MTMR6|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6806a was selected from the C-term region of human MTMR6 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Phosphatase that acts on lipids with a phosphoinositol headgroup. Acts as a negative regulator of KCNN4/KCa3.1 channel activity in CD4+ T-cells possibly by decreasing intracellular levels of phosphatidylinositol 3 phosphatase. Negatively regulates proliferation of reactivated CD4+ T-cells.|
|Cellular Location||Nucleus envelope|
|Tissue Location||Expressed in CD4+ T-cells.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The myotubularin (MTM) family constitutes one of the largest and most highly conserved protein-tyrosine phosphatase (PTP) subfamilies. Myotubularins, contain the consensus active site of tyrosine phosphatases but otherwise shows no homology to other phosphatases. PTP's usually act on substrates containing only phosphotyrosine sites, but myotubularins were shown to act on both phosphotyrosine and phosphoserine (dual specific). The enzymatic activity of myotubularins had not been demonstrated previously because it lacks catalytically active residues in tyrosine phosphatase/dual-specific phosphatase active site. The active site is however sufficiently preserved to bind phosphorylated substrates, and may protect from phosphatases. It was reported that interaction of myotubularin family members makes one of them catalytically active. The 4.8-kb MTMR6 mRNA is expressed ubiquitously. By analysis of radiation and somatic cell hybrids, the MTMR6 gene has been mapped to 13q12. MTMR6 corresponds to an EST located within a cloned region that encompasses a translocation breakpoint t(8;13) observed in 2 patients with an atypical myoproliferative disorder.
Nandurkar, H.H., et al., Proc. Natl. Acad. Sci. U.S.A. 100(15):8660-8665 (2003).Laporte, J., et al., Hum. Mol. Genet. 7(11):1703-1712 (1998).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.